Fig. 1.

Zoledronic acid and atorvastatin dose-dependently reduce breast cancer adhesion. ((A) and (B)) MDA-231 breast cancer cells were treated with zoledronic acid (1–100 µM) and atorvastatin (1–100 µM) for 24 h. Data are presented as the percentage adhesion on gelatin relative to control treated (PBS, DMSO) cells, and are mean±SD of 3 independent experiments. (C) Inhibition of mevalonate pathway was verified by assessment of RAS (arrow indicates unfarnesylated band) and ungeranylated RAP1A. GAPDH served as loading control. ^*p<0.05; ^**p<0.01; ^***p<0.001.